MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma

Expert Review of Anticancer Therapy 2016 October 4 [Epub ahead of print] [Link]

Chia PL, Russell P, Scott AM, John T

Abstract

INTRODUCTION:
Malignant mesothelioma (MM) is an aggressive malignancy of the pleura and other serosal membranes originating from mesothelial cells that, despite decades of research, continues to have limited therapeutic options and is associated with a poor prognosis. Areas covered: MMs induce a strong inflammatory response that is also associated with neoangiogenesis and activation of proangiogenic factors. Given this, several anti-angiogenic agents have been trialled in a variety of malignancies including mesothelioma. Herein we summarise the role of angiogenesis in MM and the current available data targeting these pathways. Expert commentary: The addition of bevacizumab to cisplatin/pemetrexed chemotherapy is currently a therapeutic option with a proven 2.7 month overall survival benefit in fit patients less than 75. Other antiangiogenics such as nintedinib show early promise, although the Phase III trial results are eagerly awaited before this therapy enters treatment paradigms. Beyond this, it is likely that combinations of antiangiogenics with immunotherapies will be investigated in future studies.

Both comments and trackbacks are currently closed.